Injury to the CNS triggers a sequence of cellular events in the remaining tissue, including death of neurons and profuse proliferation of astroglia. Primed by the original insult, a cascade of biochemical events takes place at the site of the injury, triggering the release of diffusible molecules that appear to regulate glial proliferation, neuronal survival, or regrowth. The response of astrocytes to injury is central to the events leading to the survival and healing of the tissue affected by the insult. Proliferation of astrocytes around the injury site contributes to the restoration of the blood-brain barrier and provision of trophic factors to the damaged tissue. Paradoxically, the same astrocytes form a bar- rier around the injury site that is almost impenetrable to the ingrowing neuritic processes. Accordingly, the elucidation of the mechanisms that control the differentiation, reactivity, and/or proliferation of astrocytes is important in the development of therapeutic procedures to enhance neuronal survival and to foster regeneration following brain trauma.
Substances that control astrocytic reactivity and/or proliferation include trophic molecules that are released by cells surrounding the injury. Fibroblast growth factors (FGFs) are typically recognized for their wide spectrum of action exerted on a large variety of cell types including astrocytes and neurons. In the brain, the best characterized member of the FGF family is basic FGF (bFGF or FGF-2), which is active as a promoter of neuronal survival and neurite extension in vitro (Walicke, 1988a,b; Grothe et al., 1989) and in viva (Sievers et al., 1987; Anderson et al., 1988; Otto et al., 1989) . FGF-2 is primarily expressed by astrocytes and appears to participate in their differentiation (Lillien and Raff, 1990; McKinnon et al., 1990) and proliferation (Morrison and De Villis, 1981) . Therefore, FGF-2 appears to be a good candidate for a role in the regulation of astrocytic function in the healthy, injured, or diseased CNS.
A large body of evidence indicates that heparan sulfate proteoglycans (HSPG) participate in the regulation of FGF-2 action (Ruoslahti and Yamagushi, 1991) . Indeed, HSPG acts as a lowaffinity receptor for FGF-2 (Moscatelli, 1987; Klagsbrun and Baird, 1991) , potentiating the action of FGF-2 and protecting it from degradation. Recent studies indicate that the binding of FGF-2 to high-affinity receptors requires the presence of heparin or cell-derived HSPG (Rapraeger et al., 1991; Yayon et al., 1991) . Apparently, heparin interacts independently with a portion of the transmembrane tyrosine kinase glycoprotein component of the FGF receptor complex (Kan et al., 1993) . Four types of high-affinity FGF receptors (FGFR) have been identified, FGFR-1 or JIs (Lee et al., 1989) , FGFR-2 or bek (Dionne et al., 1990; Mansukhani et al., 1992) , FGFR-3 (Keegan et al., 1991) , and FGFR-4 (Partanen et al., 1991) . FGFR-1 consists of three extracellular immunoglobulin-like domains, a transmembrane domain, and an intracellular tyrosine kinase domain (Lee et al., 1989; Ullrich and Schlessinger, 1990) . FGF-2 does not have a signal peptide controlling its own release from cells, and to a large extent the effect of FGF-2 appears to be regulated by the interaction with its receptor. Increasing evidence indicates that FGFR-1 is induced by brain trauma (Gomez-Pinilla and Cotman, 1992; Logan et al., 1992) and afferent activity (Van der Wal et al., 1994) , suggesting that the FGFR-1 may have a role in brain plasticity.
In the present study we present evidence supporting an action of FGF-2 on astrocytic reactivity and/or proliferation in viva Furthermore, we examine the possibility that FGF-2 on astrocytic reactivity and/or proliferation may be modulated by an interaction with extracellular matrix components. According to this hypothesis interactions between FGF-2, FGFR-1, and HSPG may regulate the action of FGF-2 in brain injury.
Material and Methods
Surgery and experimental procedures. Sprague-Dawley male rats 3-4 months old received aspiration of a small segment of the motor-sensory cortex (I .5 mm diameter, 1.7 mm deep from top of skull, 3.5 mm lateral to the midline) in both hemispheres. Groups of rats (n = 5) received a piece of Gelfoam embedded with human recombinant FGF-2 (100 rig/ml; endotoxin < 3.0 Ue/mg; UBI, NY) dissolved in PBS, heparan sulfate (HS; 10 kg/ml; sodium salt, bovine kidney; Sigma) dissolved in PBS, or both, in the right hemisphere. The wound cavity of the left hemisphere received a piece of Gelfoam embedded with saline. Group of rats (n = 4) to be used in nuclease protection assay received FGF-2, HS, or FGF-2/HS treatments bilaterally. Rats to be used as a control (n = 5) received a piece of Gelfoam embedded with saline bilaterally in the cerebral cortex. These experiments were performed according to NH1 guidelines for the care of animals and studies have been approved by the animal care committee.
Two days after surgery, rats to be used for immunohistochemical experiments were deeply anesthesized with Nembutal (75 mglkg, i.p.) and perfused with 200 ml of phosphate-buffered saline followed by 400 ml of 4% paraformaldehyde in 0.1 M Sorensen buffer; the brains were removed, postfixed for 15 min in fresh solution of the same fixative, and stored overnight in 20% sucrose. Serial coronal sections (30 pm) throughout the forebrain were cut in a cryostat and processed for FGF-2, FGFR-1, or glial fibrillary acidic protein (GFAP) immunoreactivities. Alternate sections were stained with cresyl violet to visualize the general cytoarchitecture of the areas under study. Rats to be used in nuclease protection assays were quickly decapitated, and an area (0.5 cm) of cerebral cortex around the wound cavity was dissected out and frozen in dry ice.
Immunohistochemistry. The tissue sections were first treated with 1% H,O, in cold 100% methanol to inactivate the endogenous peroxidase a&&y.
Alternate sections were then incubated overnight-in one of three antibodies: (1) a mouse monoclonal anti-FGF-2 (4 &ml; UBI, NY), which recognizes biologically active FGF-2 and hoes-not crossreact with FGF-1 (Matsuzaki et al., 1989) ; (2) a mouse monoclonal (2 yglml; UBI, NY) that specifically recognizes the external domain of the FGF receptor vlg or FGFR-1; Western immunoblot analysis determined that this antibody was able to detect 50-100 ng of human FGF receptor protein of the flR type (Hou et al., 1991) ]; (3) a rabbit monoclonal anti-GFAP (2.9 kg/ml; Dakopatts Labs, Denmark), diluted in PBS containing 0.1 Triton X-100 and 2% BSA. The sections were then rinsed three times over 30 min and incubated in rat-adsorbed biotinylated horse anti-mouse immunoglobulin G (FGF-2 and FGFR-1 immunostaining) or biotinylated goat anti-rabbit IgG (GFAP staining) for I hr. After several rinses, sections were incubated in avidin-HRP complex for 1 hr, rinsed, incubated in 3,3'-diaminobenzidine (DAB; 0.5 mg/ml in Tris buffer, 10 min), and then reacted for 5 min with fresh DAB solution containing 0.01% H,O,. All the sections were thoroughly rinsed with PBS, mounted, dehydrated with increasing gradients of ethanols, and coverslipped with Depex mounting medium. Sections were examined on an Olympus BH-2 microscope. Immunohistochemistry controls included (1) incubation in buffer excluding the primary antibody, (2) incubation with a secondary antibody against a wrong species, and (3) incubation with a preabsorbed anti&FGF-2 antisera [lo pg of recombinant FGF-2 (UBI, NY)/ml of normally diluted serum; 15 hr]. The results of these immunohistochemistry controls were consistently negative. FGF-2 staining was abolished in cell structures but was slightly increased in the extracellular matrix and blood vessels.
To further characterize the anti-FGF-2 antibody, dot blot experiments were performed (according to UBI protocols) to investigate if this antibody also binds FGF-2 complexed to heparan sulfate. Briefly, recombinant FGF-2 (6.25 pg/ml to 0.1 pglml; UBI) was combined with HS (0, 10, 100 p.g/ml; Sigma), and then the anti-FGF-2 antibody was added at a final concentration of 4 pg/ml. The signal related to the staining with the anti-FGF-2 antibody was not affected by the presence of HS. The results of these experiments showed that the binding of the anti-FGF-2 antibody to FGF-2 is independent of the presence of heparan sulfate. Double-staining immunohistochemistry.
To ascertain the cellular localization of FGF-2 or FGFR-1, sections were costained with a second antibody. An anti-GFAP antibody was used to detect astrocytes. The color reaction to detect the first antibody (anti-FGF-2) was developed with nickel chloride combined with DAB, giving a purple reaction product instead of the typical brown reaction product. Sections were thoroughly rinsed in PBS, reacted for 15 min in excess avidin, and then rinsed for another 15 min in PBS with excess biotin. After rinsing in PBS, sections were incubated overnight in anti-GFAP antibody. The rest of the process is the same as described above, except that the second antibody was detected with DAB alone, resulting in a brown reaction product.
Quanti$cation procedure. To assess the effects of the lesion and treatments, cells immunostained for GFAP, FGF-2, or FGFR-1 contained within a 0.25 mm2 area positioned at 240 pm from the edge of the lesion were counted bilaterally. Cells were counted under camera lucida microscopy at 160X magnification at four coronal planes separated by about 100 pm from each other. To minimize variability between animals, the ratio between the ipsilateral and contralateral sides to the treatment was calculated for each rat. The ratio mean values for GFAP, FGF-2, or FGFR-1 were compared across the different experimental conditions using ANOVA and Fisher's test, and the data are expressed as a percentage of controls.
N&ease protection assay. Total cellular RNA was isolated by guanidine thiocyanate extraction according to Chomczynski and Sacchi (1986) . Quantification of total RNA was performed by absorption at 260 nm. Briefly, total RNA (30 p,g) from particular brain regions was dissolved in 30 ul of hvbridization buffer (80% formamide. 40 mM PIPES pH 6.4, 460 ells sodium chloride, and' 1 mM EDTA) containing 5 pl of-a '*P-labeled FGF-2 cRNA probe (specific activity, 10h cpm/pg of RNA). After being heated at 85°C for 10 min to denature RNA. the cRNA probe was allowed to anneal the endogenous RNA at 55°C overnight. At the end of the hybridization, the solution was diluted with RNase digestion buffer containing 40 kg/ml of RNase A and 2 pg/ml of RNase T, and incubated for 30 min at 37°C. Following proteinase K (240 kg/ml) digestion, samples were extracted with phenol/chloroform and ethanol precipitated. For the pellet containing the RNA, RNA hybrid was resuspended in gel loading buffer, boiled at 85°C and separated on a 5% polyacrylamide, 7 M urea gel unit. The gel was dried and the protected fragment was visualized by autoradiography on Bmax-hyperfilm (Amersham, IL). In some experiments the same total RNA used for FGF-2 mRNA measurements was hybridized with a rat glyceraldehyde 3-phosphate dehydrogenase cRNA probe (GAPDH; Ambion, TX) to ensure that samples used for the assay contained an equivalent amount of RNA. FGF-2 mRNA contents were estimated by measuring the peak densitometry area of the autoradiogram analyzed with an image analysis system (Imaging Inc., St. Catherines, Ontario, Canada). The ratio FGF-2:GAPDH of optical densitometric values was calculated for each treatment and is expressed as relative to control.
To assess relative levels of FGF-2 mRNA expression, we used an FGF-2 32P-labeled cRNA probe prepared from cDNA templates coding the rat FGF-2 gene (kindly provided by Dr. Andrew Shimasaki et al., 1988) . A pBluescript SK+ plasmid (RObFGF503) was linearized with NcoI and then transcribed using T7 RNA polymerase to generate a 524 base antisense probe that contained a 477 base FGF-2 gene coding region. To be used as a control, a 376 base GAPDH cRNA probe was generated by transcribing with T3 RNA polymerase, a manufacturerprelinearized plasmid (Ambion, TX). Transcription reactions were performed using a Promega transcription kit (Promega, WI) and w-'~P-CTP (Amersham, IL; 800 Ci/mmol).
Results
Distribution qf FGF-2 and FGFR-1 in normal rat brain. We used an affinity-purified monoclonal antibody against the active form of FGF-2 to characterize the cellular localization of FGF-2 in the brain. Double-staining immunohistochemistry using an anti-GFAP antibody and an anti-FGF-2 antibody showed that FGF-2 immunoreactivity was present primarily in astrocytes throughout the brain (data not shown), as previously described in detail elsewhere (Gbmez-Pinilla et al., 1992) . Within single astrocytes FGF-2 staining was compartmentalized in the nuclear region. To stain cells displaying FGFR-1 immunoreactivity, we showing the effects of FGF-2 and FGF-2/HS treatments on astrocytes. The photographs were taken from the area adjacent to the wound cavity (double arrows), which was filled with a piece of Gelfoam embedded with the experimental solution. A, Sample section from a saline control animal showing the general distribution of astrocytes by the site of injury (arrows) .
B, High magnification of A displaying the typical morphology of astrocytes by the injury site. C, Effects of recombinant FGF-2 treatment on the distribution and morphology of astrocytes. FGF-2 applied within the wound cavity caused an increase in number and intensity of GFAP staining in astrocytes. D, High magnification of C showing the effects of FGF-2 treatment on the morphology of astrocytes. There was an increase in astrocytic density and intensity of GFAP staining compared with saline or HS treatments (not shown). I?, Effects of the combined application of HS and FGF-2. There was an increase in the density number of astrocytes and intensity of GFAP staining compared either with saline, HS, or FGF-2 treatments. F, High magnification of E showing the morphology of astrocytes. Scale bar (in E), 60 p,m for A, C, and E; 15 pm for B, D, and F. used a monoclonal antibody specific against FGFR-1. FGFR-1 istochemistry showed that FGFR-1 immunoreactivity (data not immunoreactivity was light and sparse in the intact brain but shown) was colocalized with GFAP immunoreactivity revealing occasionally present in isolated cells mostly within the cerebral that FGPR-1 was primarily expressed in astrocytes, as previouscortex and hippocampal formation. Figure 2 . Quantification of th e number of astrocytes immunostained with an anti-GFAP antibody near the area surrounding the wound cavity. The graph shows the effects of HS, FGF-2, and FGF/HS on the density of astrocytes, expressed as a percentage of control (saline). FGF-2 treatment elicited an increase in the number of astrocytes as compared with saline treatment, and this effect was potentiated by the combined application of FGF/HS. Statistical comparisons were performed using ANOVA and Fisher's test (**, P < 0.01). Error bars are SD.
Induction of FGF-2 and FGFR-I qfier lesion. An anti-GFAP antibody was used to evaluate changes in the astrocyte population following injury. Two days after performing a cortical lesion there was a large increase in the density of astrocytes in the area surrounding the injury site (Figs. IA, 2 These FGF-2-positive astrocytes responding to the lesion stimulus showed signs of hypertrophy such as FGF-2 staining in the cytoplasmic region and proximal processes. Two days after cortical lesion, the area surrounding the lesion also showed a large increase in the density of cells displaying FGFR-1 immunoreactivity (Figs. 5A, 6 ). The majority of these FGFR-1 cells were astrocytes as revealed by costaining with an anti-GFAP antibody (data not shown).
effects oj'exogenous FGF-2 on astrocytes, FGF-2 cells, und FGFR-1 cells. To examine a possible effect of FGF-2 on astrocytic reactivity and/or proliferation, we increased the availability of FGF-2 to the cells located near the injury site by placing FGF-2-embedded Gelfoam within the lesion cavity. Two days following the priming lesion in the cerebral cortex and FGF-2 treatment, there was an increase in the density of astrocytes immunostained with the anti-GFAP antibody as compared to control rats that received saline only (P < 0.01; Fig. 2 ). This FGF-2-induced increase of astrocytes was particularly obvious along the periphery of the cortical lesion where the FGF-2-embedded Gelfoam was applied. These astrocytes appeared to stain stronger for GFAP (Fig. IC,D) than saline-treated astrocytes (Fig.   lA,B) .
Analysis of the tissue sections stained for FGF-2 in parallel with the GFAP staining showed that the recombinant FGF-2 applied in the wound cavity also had an effect on the population of FGF-2-stained astrocytes. These astrocytes showed FGF-2 staining along their processes (Fig. 3C,D) in contrast to the typical FGF-2 staining only in the nuclear region (Fig. 3A,B) . The number of cells displaying FGF-2 staining by the lesion area was increased in the FGF-2-treated group compared to control rats treated with saline (P < 0.01; Fig. 4) .
Another set of tissue sections was stained in parallel with an anti-FGFR-1 antibody. Microscopic examination of these sections revealed that there was an induction of cells displaying FGFR-1 immunoreactivity.
These cells resembled astrocytes and developed a stronger FGFR-1 staining in the cell body and processes (Fig. 5C,D) as compared to saline-treated cells (Fig.   5A,B) . The density of FGFR-l-positive cells in the FGF-2-treated group was significantly increased relative to control rats treated with saline (P < 0.01; Fig. 6 ).
A separate group of rats (n = 4) was treated bilaterally with recombinant FGF-2 and the tissue surrounding the wound cavity removed. This tissue was assayed via nuclease protection assay to examine the relative levels of FGF-2 mRNA.
Results showed an increase in FGF-2 mRNA in the group of rats treated with FGF-2 relative to the saline control rats (optical density ratio FGF-2:GAPDH = 1.25, n = 4; Fig. 7 ).
Eflects of exogenous HS on ustrocytes, FGF-2 cells, and FGFR-I cells. Several lines of evidence indicate that HS has an important
role in the physiology of FGF-2. To test the effect of HS alone in our lesion paradigm, a piece of Gelfoam embedded with HS was applied unilaterally into the wound cavity. Quantification of the number of GFAP-stained astrocytes did not show any significant difference between the HS-treated group versus the saline-treated group of rats (Fig. 2) . Similarly, quantification of FGF-2-stained cells did not show a significant difference between HS-treated rats versus saline-treated control rats (Fig. 4) . However, analysis of the FGFR-1-immunostained cells showed a significant increase in density in the rats treated with HS as compared to the control rats treated with saline (P < 0.01; Fig.   6 ).
A group of rats was treated bilaterally with HS and the tissue surrounding the wound cavity dissected out. The tissue was analyzed using a nuclease protection assay to examine the relative levels of FGF-2 mRNA.
Results showed no apparent changes in levels of FGF-2 mRNA in the HS-treated rats relative to the saline control rats (optical density ratio FGF-2:GAPDH = 0.92, n = 4; Fig. 7 ). Effects of exogenous FGF-2 combined with HS on astrocytes, FGF-2 cells, and FGFR-I cells. Next, we examined the possibility that the combination FGF-2/HS could potentiate the action of FGF-2 alone. Accordingly FGF-2/HS was applied in a piece of Gelfoam placed into the wound cavity. The FGF-2/HS application triggered a larger increase of the same cellular parameters that had been increased by separate applications of either FGF-2 or HS. Specifically, rats receiving FGF-2/HS treatment displayed a significant increase in the number of astrocytes relative to control rats treated with saline (P < 0.01; Fig. 2 ), or rats receiving HS treatment (P < 0.01; Fig. 2 ). FGF-2-immunostained cells in the FGF-2/HS group were significantly increased in number relative to the control rats treated with saline (P < 0.01; Fig. 4) or the rats receiving HS treatment (P < 0.01; Fig. 4 ) or FGF-2 treatment (P < 0.01; Fig. 4 ). FGFR-1-immunostained cells from the FGF-2/HS group also were significantly increased in number relative to the rats receiving HS treatment (P < 0.01; Fig. 6 ) or control rats treated with saline (P < 0.01; Fig. 6 ). Immunostaining for GFAP, FGF-2, and FGFR-1 appeared much stronger in the cell bodies and processes of FGF-2/HS-treated rats as compared to saline-or HS-treated cells. The tissue surrounding the wound cavity from a separate group of rats was treated with FGF-2/HS.
A nuclease protection astrocytelike cells, expressed as a percentage of control (saline). FGF-2 applied into the wound cavity elicited an increase in the number of FGF-2 cells as compared with saline or HS treatments, and this effect was potentiated by the combined application of FGF/HS. Statistical comparisons were performed using ANOVA and Fisher's test (**, P < 0.01). Error bars are SD.
assay was used to detect relative levels of FGF-2 mRNA. Results showed a relative increase in FGF-2 mRNA in the group of rats that received FGF-2/HS treatment as compared to FGF-2-treated rats or saline control rats (Fig. 7) . The optical density ratio FGF-2:GAPDH relative to control for the different treatments was HS = 0.92, FGF-2 = 1.25, and FGF-2/HS = 1.51 (n = 4).
Discussion
Our results indicate that FGF-2 appears to have a modulatory role in astrocytic reactivity and/or proliferation following CNS traumatic injury. Application of exogenous FGF-2 in the wound cavity triggered an increase in the population of astrocytes by the lesion area. The same intervention specifically increased the number of astrocytes displaying immunoreactivities for FGF-2 and FGFR-I and also elicited an induction of FGF-2 mRNA in the tissue surrounding the lesion. The effects of FGF-2 on astrocyte reactivity and/or proliferation, and induction of FGF-2 and FGFR-1 were potentiated when recombinant FGF-2 was applied together with HS in the wound cavity.
The observation that exogenous FGF-2 promoted astrocyte reactivity and/or proliferation supports the idea that FGF-2 may stimulate astrocytic proliferation in the brain as predicted by previous studies in vitro. Morrison and De Villis (1981) have demonstrated that FGF-2 promotes proliferation of astrocytes in culture. In addition, our data demonstrate that FGF-2 induces the expression of its own mRNA, supporting the possibility that the action of FGF-2 in astrocyte proliferation may be via regulation of its own synthesis (Flott-Rahmel et al., 1992) . Furthermore, our data show that changes in FGF-2 mRNA are translated into protein since there were concomitant changes in FGF-2 immunoreactivity. Our findings are in general agreement with recent studies in culture. Gerdes et al. (1992) have shown that inhibition of the endogenous FGF-2 expression with antisense oligonucleotides causes a reduction of cell proliferation. FlottRahmel et al. (1992) have demonstrated that treatment of astrocytes or hippocampal neurons in culture with exogenous FGF-2 triggers an induction of FGF-2 gene expression, supporting an autocrine action of FGF-2.
The induction of FGFR-1 by FGF-2 application suggests that the regulation of FGF receptor may be a factor for the regulation of the action of FGF-2. FGF receptor (Gomez-Pinilla et al., 1992; Van der Wal., 1994) and its mRNA (Wanaka et al., 1990; Logan et al., 1992) are present at low levels in the intact brain; however, they are highly regulated by stimuli such as trauma (Logan et al., 1992; Gomez-Pinilla and Cotman, 1992) or physiological activity (Van der Wal et al., 1994) . Moreover, the observation that FGF-2 and its receptor were increased adds further support for an autocrine action of FGF-2 on cells.
Current information indicates that HS has a role in the regulation of the action of FGF-2 on cells; however, the mechanism involved has remained unknown. The modulatory role of HS on FGF-2 function is versatile and appears to be achieved by interacting with multiple targets along the path leading to the execution of FGF-2 action on cells. For example, HS normally binds FGF-2, which is present in the extracellular matrix or associated with cells. When FGF-2 forms a complex with HS it is more stable than FGF-2 alone and is protected from proteolytic degradation (Gospadorowicz and Cheng, 1986; Flaumenhaft et al., 1990) . Interestingly, our data demonstrate a completely new aspect of the interactions between FGF-2 and HS. That is, HS potentiates the effect that FGF-2 exerts on the induction of FGF-2, its mRNA, and its receptor. It is likely that these actions are associated with the regulation of astrocyte proliferation, since the increase in density of astrocytes elicited by FGF-2 was also potentiated by the combined application of FGF-2 and HS.
Thus, based on our results and others, it appears that the modulatory influence that HS exerts on FGF-2 action is partially achieved by an interaction of HS with FGFR. Studies in vitro (Kan et al., 1993) show that the interaction of HS with a specific sequence in one of the immunoglobulin subunits in the extracellular domain of the FGF receptor is independent of FGF binding. According to these investigators (Kan et al., 1993 ) the FGF receptor is a ternary complex of a HS, tyrosine kinase transmembrane glycoprotein, and ligand, and that HS binding domain is essential for the binding of FGE Our results are in general agreement with that study and further demonstrate that HS when combined with FGF-2 upregulates FGFR phenotypic expression.
According to our data, the action of FGF-2 may involve a proper balance between FGF-2 and HSPG. HSPGs as well as other extracellular matrix components exhibit different expression patterns (Herdon and Lander, 1990; Sheppard et al., 1991 , Fuxe et al., 1994 and different biological activities (Hondermarck et al., 1992; Lander, 1993; Letourneau et al., 1994) throughout ontogeny. For example, Nurcombe et al. (1993) have recently reported that differences in the type of HS carried by a single core protein can switch the affinity for FGF-1 or FGF-2. The changes in the affinities of HS for FGF-1 versus FGF-2 appear to be coordinated according to their particular temporal expressions, which in turn are reflected in specific functional demands. Therefore, different ratios of FGF-2 and particular types of HSPGs may be generated, which may in turn modulate the action of FGF-2 on cells. The induction of the FGF-2/FGFR system by HS is extremely significant in the context of the regulation of the FGF system. The presence of regulatory mechanisms to precisely control FGF-2 signal transduction is important, since FGF-2 is widely distributed in the brain and is very effective in various cellular processes. Increasing evidence indicates that glycosaminoglycans are not randomly distributed in the brain, and their expressions appear to be regulated by functional demand, in particular during de- velopment (Herdon and Lander, 1990; Sheppard et al., 1991;  resent an efficient physiological mechanism to regulate the Lander, 1993; Fuxe et al., 1994; Letourneau et al., 1994 Figure 6 . Quantification of the number of FGFR-l-immunostained ceils by the area surrounding the wound cavity. The graph shows the effects of HS, FGF-2, and FGF/HS on the densitv of FGFR-l-oositive astrocytic-like cells, expressed as a percentage of control (saline). FGF-2 treatment elicited an increase in the number of FGFR-1 cells compared with saline treatment. The application of HS also elicited an increase in FGFR-1 cell density as compared with saline controls. The effects of FGF-2 and HS were potentiated by the combined application of FGFMS. Statistical comparisons were performed using ANOVA and Fisher's test (**, P < 0.01). Error bars are SD.
emerging evidence suggests that the action of FGF-2 is associated with molecular cascades involving other growth factor molecules (Cross and Dexter, 1991) . For example, the FGF family has other members such as FGF-I and FGF-5 that interact with common receptors. It has been reported that FGF-1 and FGF-5 compete with FGF-2 for the binding to the FGFR-1 receptor (Clements et al., 1993) , suggesting that a balance between different factors and FGFR-1 regulates their respective functions. There are also several described interactions between FGF-2 and other growth factor such as NGE PDGE TGFBl, EGE CNTE and LIF that are associated with the physiology of astrocytes. For example, in contrast to FGF-2, application of TGFBl into a wound cavity dramatically decreases astrocytosis (Lindholm et al., 1992) . Paradoxically, TGFB 1 probably indirectly helps FGF-2 by protecting the integrity of the extracellular matrix (Sporn and Roberts, 1991) . The interaction between FGF-2 and TGFBl can be complex considering that TGFBl may potentiate (Labourdette et al., 1990; Lefebvre et al., 1991; Saunders and D'Amore, 1991) or inhibit (Baird and Durkin, 1986 ) the action of FGF-2 on cells. TGFBl can enhance the responsiveness to FGF-2 in certain cells, that is, astroblasts that are normally insensitive to FGF-2 (Labourdette et al., 1990) . Therefore, the elucidation of the role of FGF-2 in molecular cascades is important to identify the signals that control astrocytosis and thus to design appropriate therapeutic applications.
Information presented in this study suggests a pivotal role of FGF-2 in events related to control of astrocytosis in vivo. According to studies in vitro the action of FGF-2 on astrocytes is diverse and includes effects on proliferation (Morrison et al., 1986) , migration (Senior et al., 1986) , and regulation of other trophic molecules (Yoshida and Gage, 1991) . During development, the presence of FGF-2 has been shown to be a determining factor for the differentiation of progenitor cells into type-2 astrocytes or oligodendrocytes (Lillien and Raff, 1990; McKinnon et al., 1990) . According to our studies in vivo (G6mez-Pinilla et al., 1994) , FGF-2 phenotypic expression appears on astrocytes by the time of proliferation, supporting a role of FGF-2 in this process. The present study suggests that FGF-2 and its receptor lane 5), and the tissue surrounding the wound cavity was assayed with a nuclease protection assay. The treatment with FGF-2 triggered an increase in FGF-2 mRNA (lane 4), and this effect was potentiated by the combined application of FGF-2 and HS (lane 5). A 524 base 32P-labeled antisense probe that contained a 477 base FGF-2 gene coding region was used to assess relative levels of FGF-2 mRNA expression. Lane 1 of the gel displays the unprotected FGF-2 cRNA probe, and lanes 2-5 display the protected FGF-2 cRNA fragment. Size markers are indicated at the far right as a reference. At the bottom is shown a separate assay performed using the same total RNA hybridized with a GAPDH cRNA probe, to control for using equal amounts of RNA for each condition.
are involved in the process of astrocyte reactivity and/or proliferation in vivo, and this action appears to be regulated by HS. Therefore, FGF-2 via interaction with extracellular matrix components, and probably other factors, may be involved in a cascade of events that regulate development and plasticity of glial and neuronal cells in the CNS.
